Meeting
2014 ASCO Annual Meeting
Phase I open-label, multiple ascending dose trial of MSB0010718C, an anti-PD-L1 monoclonal antibody, in advanced solid malignancies.
Authors
Christopher Ryan Heery
Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD
Christopher Ryan Heery , Geraldine Helen O'Sullivan Coyne , Ravi Amrit Madan , Jeffrey Schlom , Anja von Heydebreck , Jean-Marie Cuillerot , Helen Sabzevari , James L. Gulley
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Immunotherapy
Track
Developmental Therapeutics
Sub Track
Immunotherapy and Biologic Therapy
Clinical Trial Registration Number
NCT01772004
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 3064)
DOI
10.1200/jco.2014.32.15_suppl.3064
Abstract #
3064
Poster Bd #
131
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Pharmacokinetic profile and receptor occupancy of avelumab (MSB0010718C), an anti-PD-L1 monoclonal antibody, in a phase I, open-label, dose escalation trial in patients with advanced solid tumors.
First Author: Christopher Ryan Heery
Poster
2020 ASCO Virtual Scientific Program
Open-label, phase I study evaluating feasibility and safety of subcutaneous IMP321 (LAG-3Ig fusion protein, eftilagimod alpha) combined with avelumab in advanced stage solid tumor entities: Results from stratum D of the INSIGHT platform trial.
First Author: Thorsten Oliver Goetze
Poster
2015 ASCO Annual Meeting
Phase I, open-label, multi-ascending dose trial of avelumab (MSB0010718C), an anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors.
First Author: Kohei Shitara
Poster
2023 ASCO Annual Meeting
A phase 1 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of LB4330, a peptide fused to CLDN18.2 antibody targeting the tumor antigen associated CD8+t CELLS in patients with advanced solid tumors.
First Author: Jiajian Liu